These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
78 related articles for article (PubMed ID: 8627880)
21. Immunohistochemical comparative analysis of transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor in normal, hyperplastic and neoplastic human prostates. De Miguel P; Royuela ; Bethencourt R; Ruiz A; Fraile B; Paniagua R Cytokine; 1999 Sep; 11(9):722-7. PubMed ID: 10479409 [TBL] [Abstract][Full Text] [Related]
22. An organ culture system for the study of programmed cell death in the rat ventral prostate. Martikainen P; Isaacs JT Endocrinology; 1990 Sep; 127(3):1268-77. PubMed ID: 2201533 [TBL] [Abstract][Full Text] [Related]
23. Phosphotyrosine antibodies preferentially react with basal epithelial cells in the dog prostate. Landry F; Chapdelaine A; Bégin LR; Chevalier S J Urol; 1996 Jan; 155(1):386-90. PubMed ID: 7490893 [TBL] [Abstract][Full Text] [Related]
24. Anthocyanin extracted from black soybean reduces prostate weight and promotes apoptosis in the prostatic hyperplasia-induced rat model. Jang H; Ha US; Kim SJ; Yoon BI; Han DS; Yuk SM; Kim SW J Agric Food Chem; 2010 Dec; 58(24):12686-91. PubMed ID: 21121678 [TBL] [Abstract][Full Text] [Related]
25. Secretion of insulin-like growth factors and their binding proteins by human normal and hyperplastic prostatic cells in primary culture. Boudon C; Rodier G; Lechevallier E; Mottet N; Barenton B; Sultan C J Clin Endocrinol Metab; 1996 Feb; 81(2):612-7. PubMed ID: 8636277 [TBL] [Abstract][Full Text] [Related]
26. New histopathological experimental model for benign prostatic hyperplasia: stromal hyperplasia in rats. Mori F; Oda N; Sakuragi M; Sakakibara F; Kiniwa M; Miyoshi K J Urol; 2009 Feb; 181(2):890-8. PubMed ID: 19095262 [TBL] [Abstract][Full Text] [Related]
27. Mechanisms of synergism between antagonists of growth hormone-releasing hormone and antagonists of luteinizing hormone-releasing hormone in shrinking experimental benign prostatic hyperplasia. Rick FG; Schally AV; Block NL; Abi-Chaker A; Krishan A; Szalontay L Prostate; 2013 Jun; 73(8):873-83. PubMed ID: 23280565 [TBL] [Abstract][Full Text] [Related]
28. Permissive and instructive induction of adult rodent prostatic epithelium by heterotypic urogenital sinus mesenchyme. Hayashi N; Cunha GR; Parker M Epithelial Cell Biol; 1993 Apr; 2(2):66-78. PubMed ID: 8353595 [TBL] [Abstract][Full Text] [Related]
29. LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia. Rick FG; Schally AV; Block NL; Halmos G; Perez R; Fernandez JB; Vidaurre I; Szalontay L Prostate; 2011 May; 71(7):736-47. PubMed ID: 20945403 [TBL] [Abstract][Full Text] [Related]
30. Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage. Rick FG; Szalontay L; Schally AV; Block NL; Nadji M; Szepeshazi K; Vidaurre I; Zarandi M; Kovacs M; Rekasi Z J Urol; 2012 Apr; 187(4):1498-504. PubMed ID: 22341819 [TBL] [Abstract][Full Text] [Related]
31. Ursolic acid reduces prostate size and dihydrotestosterone level in a rat model of benign prostatic hyperplasia. Shin IS; Lee MY; Jung DY; Seo CS; Ha HK; Shin HK Food Chem Toxicol; 2012 Mar; 50(3-4):884-8. PubMed ID: 22266360 [TBL] [Abstract][Full Text] [Related]
32. Prostate growth inhibition by subtype-selective alpha(1)-adrenoceptor antagonist naftopidil in benign prostatic hyperplasia. Kojima Y; Sasaki S; Oda N; Koshimizu TA; Hayashi Y; Kiniwa M; Tsujimoto G; Kohri K Prostate; 2009 Oct; 69(14):1521-8. PubMed ID: 19544328 [TBL] [Abstract][Full Text] [Related]
33. Fibroblast growth factor receptor 2 tyrosine kinase is required for prostatic morphogenesis and the acquisition of strict androgen dependency for adult tissue homeostasis. Lin Y; Liu G; Zhang Y; Hu YP; Yu K; Lin C; McKeehan K; Xuan JW; Ornitz DM; Shen MM; Greenberg N; McKeehan WL; Wang F Development; 2007 Feb; 134(4):723-34. PubMed ID: 17215304 [TBL] [Abstract][Full Text] [Related]
34. Vitamin C supplementation prevents testosterone-induced hyperplasia of rat prostate by down-regulating HIF-1alpha. Li SH; Ryu JH; Park SE; Cho YS; Park JW; Lee WJ; Chun YS J Nutr Biochem; 2010 Sep; 21(9):801-8. PubMed ID: 19716283 [TBL] [Abstract][Full Text] [Related]
35. Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues. Hahn D; Simak R; Steiner GE; Handisurya A; Susani M; Marberger M J Urol; 2000 Aug; 164(2):506-10. PubMed ID: 10893635 [TBL] [Abstract][Full Text] [Related]
36. The prevention and treatment effects of tanshinone IIA on oestrogen/androgen-induced benign prostatic hyperplasia in rats. Wang C; Du X; Yang R; Liu J; Xu D; Shi J; Chen L; Shao R; Fan G; Gao X; Tian G; Zhu Y; Zhang J J Steroid Biochem Mol Biol; 2015 Jan; 145():28-37. PubMed ID: 25290459 [TBL] [Abstract][Full Text] [Related]
37. Regional variations of insulin-like growth factor I (IGF-I), IGF-II, and receptor type I in benign prostatic hyperplasia tissue and their correlation with intraprostatic androgens. Monti S; Di Silverio F; Iraci R; Martini C; Lanzara S; Falasca P; Poggi M; Stigliano A; Sciarra F; Toscano V J Clin Endocrinol Metab; 2001 Apr; 86(4):1700-6. PubMed ID: 11297606 [TBL] [Abstract][Full Text] [Related]
38. Antiproliferative and apoptotic effects of the herbal agent Pygeum africanum on cultured prostate stromal cells from patients with benign prostatic hyperplasia (BPH). Quiles MT; Arbós MA; Fraga A; de Torres IM; Reventós J; Morote J Prostate; 2010 Jul; 70(10):1044-53. PubMed ID: 20503393 [TBL] [Abstract][Full Text] [Related]
39. p53 adenoviral vector (Ad-CMV-p53) induced prostatic growth inhibition of primary cultures of human prostate and an experimental rat model. Shirakawa T; Gotoh A; Gardner TA; Kao C; Zhang ZJ; Matsubara S; Wada Y; Hinata N; Fujisawa M; Hanioka K; Matsuo M; Kamidono S J Gene Med; 2000; 2(6):426-32. PubMed ID: 11199263 [TBL] [Abstract][Full Text] [Related]
40. Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Carducci MA; Nelson JB; Chan-Tack KM; Ayyagari SR; Sweatt WH; Campbell PA; Nelson WG; Simons JW Clin Cancer Res; 1996 Feb; 2(2):379-87. PubMed ID: 9816181 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]